GlassScriptPhysician profile
Steven Harry Weitz
NPI 1093765406
$7,851.55
in general payments reported to CMS, 2019-2025
33 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $408 · 2021: $656 · 2022: $1,519 · 2023: $1,249 · 2024: $1,605 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,334.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $905.52 | 2019-2025 | Pascal |
| Terumo Medical Corporation | $806.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $724.98 | 2019-2025 | |
| Shockwave Medical, INC | $671.36 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.70 | 2019-2025 | Jardiance |
| Abiomed | $491.86 | 2019-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $461.62 | 2019-2025 | Lokelma, Wainua, Farxiga |
| Amgen INC. | $368.26 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $293.28 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $291.78 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $233.18 | 2021-2022 | |
| Abbott Laboratories | $200.84 | 2019-2025 | Navitor, Mitraclip, Perclose Prostyle |
| Chiesi USA, INC. | $180.68 | 2019-2023 | Kengreal |
| Inari Medical, INC. | $170.18 | 2019-2021 | |
| Pfizer INC. | $168.52 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $150.82 | 2023-2025 | Verquvo, Winrevair |
| Medtronic, INC. | $144.91 | 2024-2025 | Corevalve Evolut R, Onyx Frontier |
| Regeneron Healthcare Solutions, INC. | $136.24 | 2019 | |
| Boston Scientific Corporation | $111.80 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $103.48 | 2019-2025 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $84.84 | 2023-2024 | Inpefa |
| Irhythm Technologies, INC. | $83.46 | 2022-2023 | Zio Xt Patch |
| Medtronic Vascular, INC. | $77.47 | 2019-2020 | |
| Amarin Pharma, INC. | $64.47 | 2019-2020 | |
| Bridgebio Pharma, INC. | $42.57 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $38.77 | 2025 | Onpattro |
| Cvrx, INC. | $37.14 | 2022-2023 | Barostim Neo System |
| Teleflex LLC | $36.26 | 2024 | Manta |
| Kiniksa Pharmaceuticals International, Plc | $32.84 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $24.16 | 2025 | |
| Atricure, INC. | $20.31 | 2025 | Atriclip Laa Exclusion System |
| Bayer Healthcare Pharmaceuticals INC. | $18.20 | 2025 | |
| Sanofi-Aventis U.S. LLC | $16.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Weitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.